Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Background Richter transformation (RT) describes the development of an aggressive lymphoma, in most cases a diffuse large B cell lymphoma (DLBCL) or Hodgkin's lymphoma (HL), in patients (pts) with chronic lymphocytic leukemia (CLL). Pts with RT have a dismal prognosis with chemoimmunotherapy (C...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2023-11, Vol.142 (Supplement 1), p.204-204
Main Authors: Al-Sawaf, Othman, Ligtvoet, Rudy, Robrecht, Sandra, Stumpf, Janina, Fink, Anna Maria, Tausch, Eugen, Schneider, Christof, Böttcher, Sebastian, Mikusko, Martin, Ritgen, Matthias, Schetelig, Johannes, Von Tresckow, Julia, Vehling-Kaiser, Ursula, Wendtner, Clemens-Martin, Fischer, Kirsten, Kreuzer, Karl Anton, Stilgenbauer, Stephan, Staber, Philipp Bernhard, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara F.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Richter transformation (RT) describes the development of an aggressive lymphoma, in most cases a diffuse large B cell lymphoma (DLBCL) or Hodgkin's lymphoma (HL), in patients (pts) with chronic lymphocytic leukemia (CLL). Pts with RT have a dismal prognosis with chemoimmunotherapy (CIT) like R-CHOP, with overall response rates (ORR) of
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2023-188705